Active, not recruitingPhase 2NCT06721156
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Studying Early-onset autosomal dominant Alzheimer disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- MK-1167(drug)
- Enrollment
- 350 target
- Eligibility
- 55-90 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona, United States
- Irvine Clinical Research ( Site 0104), Irvine, California, United States
- Anderson Clinical Research ( Site 0164), Redlands, California, United States
- California Neuroscience Research ( Site 0118), Sherman Oaks, California, United States
- JEM Research Institute / Headlands Research Network ( Site 0108), Atlantis, Florida, United States
- Brain Matters Research-Neurology ( Site 0150), Delray Beach, Florida, United States
- Neuropsychiatric Research Center of Southwest Florida ( Site 0152), Fort Myers, Florida, United States
- Indago Research & Health Center, Inc ( Site 0128), Hialeah, Florida, United States
- K2 Medical Research THE VILLAGES ( Site 0166), Lady Lake, Florida, United States
- K2 Medical Research ( Site 0103), Maitland, Florida, United States
- Premier Clinical Research Institute ( Site 0114), Miami, Florida, United States
- Aqualane Clinical Research ( Site 0116), Naples, Florida, United States
- Headlands Research Orlando ( Site 0169), Orlando, Florida, United States
- Brain Matters Research ( Site 0151), Stuart, Florida, United States
- K2 Medical Research ( Site 0165), Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06721156 on ClinicalTrials.govOther trials for Early-onset autosomal dominant Alzheimer disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05643144Enhancing Shared Decision-making to Guide Care for People With Dementia and DiabetesIndiana University
- RECRUITINGNANCT07294885Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's DiseaseGeneral Hospital of Shenyang Military Region
- RECRUITINGNANCT07532590Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content.Casa di Cura Dott. Pederzoli
- ENROLLING BY INVITATIONNCT07314190Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental DisorderFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ENROLLING BY INVITATIONNANCT07425106Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)Duke University
- RECRUITINGPHASE1NCT07328451A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's DiseaseDenali Therapeutics Inc.
- RECRUITINGPHASE1NCT07234942A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)Hoffmann-La Roche
- RECRUITINGNCT07207642Sweet Night (Musical Diffusion by Caregivers ): Effects of Musical Diffusion by Caregivers on Sleep Onset and Behavioral Regulation in a Protected LivingCentre Hospitalier Universitaire de Saint Etienne
See all trials for Early-onset autosomal dominant Alzheimer disease →